RespireRx Pharmaceuticals Inc (fka RSPI)

[striaterminalis]

40 may be a bit too ebullient, but I have to say I find the gist of the scenario believable. After skimming through the presentation yesterday, I find myself in the odd state of mind of being impressed by Stoll and COR. I've been on the fence about management, but when you consider what Stoll has done after the ADHD debacle, you have to admit that he has (as they say in sports all too often now) put COR in a position to succeed. They have good low and high impacts coming on line, they are testing them to make sure they don't create that artifact that seems to trigger a special FDA neurosis, and they are in the midst of what must be considered a slam dunk RD trial (at least as "slam dunky" as you can get in biotech) that may resurrect the reputation of Ampakines in one stroke.

So, after holding COR for longer than anyone should be comfortable admitting, I have to say that now, finally, I'm impressed. The RD trial could be the turning point we have all been waiting for. If this is Stoll's work, good job. He handed over a good substrate for Varney to work with.